通过激活HIF1通路,FSTL3促进结直肠癌的发生
Xiang-Rong Luo1, Li-Zhe Huang2, Jie Yin3
1Department of Colorectal & Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, PR China; The Central Hospital of Shaoyang, No. 36, Hongqi Road, Shaoyang City, Hunan Province 422000, PR China.
Gene
|March 28, 2025
概括
富利斯塔丁类3 (FSTL3) 通过激活缺氧诱导因子1α (HIF1α) 途径促进结肠直肠癌 (CRC) 的生长和扩散. 用KC7F2抑制HIF1α可以逆转这些效应,这表明FSTL3是CRC的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 福利斯塔丁类3 (FSTL3) 与瘤进展有关,但其在结直肠癌 (CRC) 中的具体作用和与缺氧诱导因子1α (HIF1α) 途径的联系尚不清楚.
- HIF1α通路对于CRC适应缺氧至关重要,驱动血管新生,上皮-介质细胞过渡 (EMT) 和代谢变化.
研究的目的:
- 研究FSTL3在结直肠癌进展中的作用.
- 确定FSTL3与CRC中的HIF1α信号通路之间的关系.
- 评估FSTL3作为潜在的预后生物标志物和CRC的治疗点.
主要方法:
- 对FSTL3表达和与临床结果相关性的TCGA和GSE39582数据集的分析.
- 使用CRC细胞系 (HCT15,HCT116,LOVO,Caco2) 进行体外研究,以评估FSTL3过度表达和击倒对细胞行为的影响.
- 转录基因组测序和西部污染,以阐明分子机制.
- 在体内实验中使用异种移植和尾静脉转移模型,有或没有HIF1α抑制剂KC7F2治疗.
主要成果:
- 在CRC组织中,FSTL3的调节显著上升,并与生存率低下和攻击性特征有关.
- FSTL3过度表达增强了CRC细胞的增殖,迁移和细胞周期进展,而敲击抑制了这些效应并诱导了亡.
- FSTL3通过调节HIF1α,ANGPT2和HK3 - - 血管生成和糖解的关键调节者 - - 来激活HIF1α通路.
- 通过KC7F2抑制HIF1α逆转了FSTL3诱导的瘤效应在体外,并在体内抑制瘤生长和转移.
结论:
- 通过HIF1α信号通路,FSTL3促进结直肠癌的进展.
- FSTL3作为CRC的潜在预后生物标志物.
- 准FSTL3或HIF1α通路为结直肠癌提供了一个有前途的治疗策略.
相关概念视频
lncRNA - Long Non-coding RNAs
7.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.5K
Loss of Tumor Suppressor Gene Functions
4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.9K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Cancer-Critical Genes II: Tumor Suppressor Genes
8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81


